Abrocitinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Abrocitinib and local guidelines before prescribing.
JAK inhibitor
Mechanism
JAK1 inhibitor.
Uses
Moderate to severe atopic dermatitis.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Nausea, headache, acne, infections, VTE.
Interactions
CYP2C19 inhibitors raise levels.
Contraindications and cautions
Active infection
Monitoring
FBC, lipids
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Reduce dose in renal impairment
Overdose and reversal
Supportive
Special advice
MHRA JAK caution groups.
More from the textbook: uses, cautions and other points
- Oral JAK inhibitors - abrocitinib , upadacitinib , baricitinib - effective; MHRA advice: use in people over 65 , smokers, or those with cardiovascular or cancer risk factors only if no suitable alternative (risk of MACE, VTE, cancer, serious infection).
Dermatology: Skin basics, eczema and psoriasis - Abrocitinib / upadacitinib / baricitinib | Oral JAK inhibitors for eczema; caution over 65, smokers, CV or cancer risk.
Dermatology: Skin basics, eczema and psoriasis - NICE TAs: Dupilumab, tralokinumab, lebrikizumab, abrocitinib, upadacitinib (atopic dermatitis); biologics for psoriasis
Dermatology: Skin basics, eczema and psoriasis
Where it is discussed in the book
- Dermatology: Skin basics, eczema and psoriasis (3 mentions)